.jpg?format=webp&width=780)
Cardiac implantable electronic device (CIED) therapy is fundamental to the management of LMNA‐cardiomyopathy due to the high frequency of atrioventricular block and ventricular tachyarrhythmias. The study aims to define the role of cardiac resynchronization therapy (CRT) in impacting heart failure in LMNA‐cardiomyopathy. Systolic function improves in patients with LMNA‐cardiomyopathy who undergo CRT, especially with strong guideline indications for implantation. Post CRT improvements in LVEF are associated with survival benefits in this population with otherwise limited options.
Like
Save
Share